Open label, Phase I, multicenter study, 2 arms with a dose escalation part and a dose expansion part.
Intervention
Arm A: 3 days on/ 4 days off, max 6 cycles
Arm B: continuous dosing
Key outcome parameters
Safety and tolerability of IAG933
Key inclusion criteria
Advanced (unresectable or metastatic) mesothelioma, or solid tumors harboring NF2/LATS1/LATS2 truncating mutations or deletions or functional YAP/TAZ fusions
Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study
ECOG performance status 0 or 1
Key exclusion criteria
Presence of symptomatic CNS metastases, or CNS tumors or metastases that require local CNS- directed therapy, or increasing doses of corticosteroids 2 weeks prior to study entry.
